https://efba.uk/blog/sleep-stress-iv-therapy/ 2026-09-06 monthly 0.7 https://efba.uk/assets/img/blog/sleep-stress-iv-therapy-cover.webp Sleep and stress IV therapy — why brain tryptophan entry is governed by the tryptophan to large-neutral-amino-acid ratio rather than the dose, what the 1991 and 1992 human infusion studies measured, what the glycine and magnesium sleep trials found and by which route, and the evidence graded by ingredient and route https://efba.uk/blog/collagen-iv-therapy/ 2026-08-30 monthly 0.7 https://efba.uk/assets/img/blog/collagen-iv-therapy-cover.webp Collagen IV therapy — why a 300 kDa triple helix cannot be infused, what a collagen drip actually contains, what the oral peptide meta-analyses found once funding source was separated out, and the evidence graded by indication and route https://efba.uk/blog/biotin-iv-therapy/ 2026-08-23 monthly 0.7 https://efba.uk/assets/img/blog/biotin-iv-therapy-cover.webp Biotin IV therapy — the carboxylase reactions biotin serves, the oral versus intravenous bioavailability data, what the hair and nail trials found, and the immunoassay interference the FDA has warned about https://efba.uk/blog/l-carnitine-iv-therapy/ 2026-08-16 monthly 0.7 https://efba.uk/assets/img/blog/l-carnitine-iv-therapy-cover.webp L-carnitine IV therapy — the carnitine shuttle, the muscle uptake ceiling, the two licensed deficiency indications, and evidence graded by indication https://efba.uk/ 2026-05-18 weekly 1.0 https://efba.uk/knowledge-bank/ 2026-05-18 weekly 0.8 https://efba.uk/catalogue/ 2026-06-17 monthly 0.9 https://efba.uk/assets/img/products/ivixir-to-infinity-md.webp IVIXIR To Infinity MD — NAD+, carnosine and vitamin C anti-aging concept https://efba.uk/assets/img/products/ivixir-nad-300-md.webp IVIXIR NAD+ 300 MD — NAD+ cellular energy and longevity concept https://efba.uk/assets/img/products/ivixir-myersence-md.webp IVIXIR MyerSence MD — Myers' Cocktail micronutrient concept https://efba.uk/blog/ 2026-08-09 weekly 0.7 https://efba.uk/blog/magnesium-iv-therapy/ 2026-08-09 monthly 0.7 https://efba.uk/assets/img/blog/magnesium-iv-therapy-cover.webp Magnesium IV therapy — eclampsia and torsades indications, the asthma evidence split, and dosing and hypermagnesaemia limits https://efba.uk/blog/amino-acid-iv-therapy/ 2026-08-03 monthly 0.7 https://efba.uk/assets/img/blog/amino-acid-iv-therapy-cover.webp Amino acid IV therapy — glutamine critical-care harm signal, PROTECTION kidney-protection trial, and evidence-graded dosing by molecule https://efba.uk/blog/b12-folate-methylation-iv-therapy/ 2026-07-27 monthly 0.7 https://efba.uk/assets/img/blog/b12-folate-methylation-iv-therapy-cover.webp Vitamin B12 and folate IV therapy — methylation cycle, route of administration, homocysteine outcome trials and evidence-graded dosing https://efba.uk/blog/alpha-lipoic-acid-iv-therapy/ 2026-07-19 monthly 0.7 https://efba.uk/assets/img/blog/alpha-lipoic-acid-iv-therapy-cover.webp Alpha-lipoic acid IV therapy — mechanism, decades of diabetic neuropathy trial evidence and dosing for intravenous ALA infusion https://efba.uk/blog/nad-iv-therapy/ 2026-07-12 monthly 0.7 https://efba.uk/assets/img/blog/nad-iv-therapy-cover.webp NAD+ IV therapy — mechanism, the 2024 head-to-head trial and dosing for intravenous NAD+ infusion https://efba.uk/blog/vitamin-c-iv-therapy/ 2026-07-05 monthly 0.7 https://efba.uk/assets/img/blog/vitamin-c-iv-therapy-cover.webp High-dose IV vitamin C — mechanism, clinical evidence and dosing for ascorbate infusion https://efba.uk/blog/glutathione-iv-therapy/ 2026-06-29 monthly 0.7 https://efba.uk/assets/img/blog/glutathione-iv-therapy-cover.webp Glutathione IV therapy — mechanism, clinical evidence and dosing for the body's master antioxidant https://efba.uk/blog/myers-cocktail-iv-therapy/ 2026-06-22 monthly 0.7 https://efba.uk/assets/img/blog/myers-cocktail-iv-therapy-cover.webp Myers' cocktail — ingredients, doses and evidence for IV micronutrient therapy https://efba.uk/blog/nad-vs-nmn-longevity/ 2026-06-18 monthly 0.6 https://efba.uk/assets/img/blog/nad-vs-nmn-longevity-cover.webp NAD+ vs NMN — an evidence-based comparison for longevity practice https://efba.uk/legal/privacy-policy.html 2026-05-13 monthly 0.4 https://efba.uk/legal/terms.html 2026-05-13 monthly 0.4 https://efba.uk/legal/legal-notice.html 2026-05-13 monthly 0.3